More deaths, no benefit from malaria drug in VA virus study (update)
MedicalXpress Breaking News-and-Events Apr 24, 2020
A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large analysis of its use in US veterans hospitals. There were more deaths among those given hydroxychloroquine vs standard care, researchers reported.
About 28% who were given hydroxychloroquine plus usual care died, vs 11% of those getting routine care alone. About 22% of those getting the drug plus azithromycin died too, but the difference between that group and usual care was not considered large enough to rule out other factors that could have affected survival.
Hydroxychloroquine made no difference in the need for a breathing machine, either.
Researchers did not track side effects, but noted a hint that hydroxychloroquine might have damaged other organs. The drug has long been known to have potentially serious side effects, including altering the heartbeat in a way that could lead to sudden death.
Earlier this month, scientists in Brazil stopped part of a study testing chloroquine, an older drug similar to hydroxychloroquine, after heart rhythm problems developed in one-quarter of people given the higher of two doses being tested.
Many doctors have been leery of the drug.
At the University of Wisconsin, Madison, "I think we're all rather underwhelmed" at what's been seen among the few patients there who've tried it, said Dr. Nasia Safdar, medical director of infection control and prevention.
Patients asked about it soon after Trump started promoting its use, "but now I think that people have realized we don't know if it works or not" and needs more study, said Safdar, who had no role in the VA analysis.
The NIH and others have more rigorous tests underway.
—Marilynn Marchione
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries